Conclusions
In this randomized clinical trial, NVX-CoV2373 was safe, immunogenic, and efficacious in preventing COVID-19, including the predominant Delta variant, in adolescents. NVX-CoV2373 is currently authorized for emergency use in the US among adults and adolescents 12 years or older.